Abdala, the first Cuban and Latin American vaccine against covid-19, celebrates this Saturday the first anniversary of its approval by the local regulatory authority for its emergency use in the mass immunization campaign on the island.
This vaccine -created and manufactured by the Center for Genetic Engineering and Biotechnology (CIGB)- has shown an efficacy of 92.28% in clinical trials. In its last phase of testing, 48,000 volunteers aged 19 to 80 participated.
–
Related posts:
Nutrition and Weight Loss After 40: Choosing the Right Foods and Avoiding Weight-Gain Traps
China's Beef Prices Hit Bottom and Expected to Rebound: Market Analysis and Export trends
Corona and school: Virologist Brinkmann calls for better tests | NDR.de - news
Donation - District Association Meiningen eV
